QUARTERLY REPORT

Q2 2025 — Quarterly report

Q2 2025PDF · 30 pages248 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________
FORM 10-Q
__________________________________________________________
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2025
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
Commission File Number: 1-10864
__________________________________________________________
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
__________________________________________________________
Delaware 41-1321939
(State or other jurisdiction of
incorporation or organization) (I.R.S. Employer
Identification No.)
1 Health Drive
55344
655 New York Avenue NW
20001	Eden Prairie, Minnesota Washington, DC
(Address of principal executive offices) (Zip Code) (Address of principal executive offices) (Zip Code)
(800) 328-5979
(Registrant’s telephone number, including area code)
_________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, $.01 par value UNH New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐
Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of July 31, 2025, there were 905,673,625 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.

-- 1 of 30 --

UNITEDHEALTH GROUP
Table of Contents
Page
Part I. Financial Information
Item 1. Financial Statements (unaudited) ......................................................................................................................... 1
Condensed Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 ..................................... 1
Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2025 and
2024 ................................................................................................................................................................. 2
Condensed Consolidated Statements of Comprehensive Income for the Three and Six Months Ended June
30, 2025 and 2024............................................................................................................................................. 3
Condensed Consolidated Statements of Changes in Equity for the Three and Six Months Ended June 30,
2025 and 2024................................................................................................................................................... 4
Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 .......... 6
Notes to the Condensed Consolidated Financial Statements................................................................................ 7
1. Basis of Presentation.................................................................................................................................... 7
2. Investments ................................................................................................................................................. 8
3. Fair Value .................................................................................................................................................... 10
4. Medical Costs Payable................................................................................................................................. 11
5. Short-Term Borrowings and Long-Term Debt............................................................................................ 12
6. Dividends ..................................................................................................................................................... 12
7. Commitments and Contingencies ................................................................................................................ 12
8. Held for Sale ................................................................................................................................................ 13
9. Segment Financial Information ................................................................................................................... 14
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations .............................. 16
Item 3. Quantitative and Qualitative Disclosures About Market Risk ............................................................................. 25
Item 4. Controls and Procedures....................................................................................................................................... 25
Part II. Other Information
Item 1. Legal Proceedings ................................................................................................................................................ 26
Item 1A. Risk Factors .......................................................................................................................................................... 26
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.............................................................................. 26
Item 5. Other Information................................................................................................................................................. 26
Item 6. Exhibits................................................................................................................................................................. 27
Signatures............................................................................................................................................................................... 28

-- 2 of 30 --

PART I
ITEM 1. FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data) June 30,
2025 December 31,
2024
Assets
Current assets:
Cash and cash equivalents ...................................................................................................................... $ 28,596 $ 25,312
Short-term investments........................................................................................................................... 3,424 3,801
Accounts receivable, net......................................................................................................................... 24,142 22,365
Other current receivables, net................................................................................................................. 28,582 26,089
Prepaid expenses and other current assets.............................................................................................. 8,955 8,212
Total current assets ......................................................................................................................................... 93,699 85,779
Long-term investments................................................................................................................................... 52,466 52,354
Property, equipment and capitalized software, net......................................................................................... 10,923 10,553
Goodwill ......................................................................................................................................................... 107,677 106,734
Other intangible assets, net............................................................................................................................. 22,510 23,268
Other assets..................................................................................................................................................... 21,298 19,590
Total assets .................................................................................................................................................... $ 308,573 $ 298,278
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable............................................................................................................................. $ 38,427 $ 34,224
Accounts payable and accrued liabilities................................................................................................ 34,330 34,337
Short-term borrowings and current maturities of long-term debt........................................................... 5,698 4,545
Unearned revenues ................................................................................................................................. 3,032 3,317
Other current liabilities........................................................................................................................... 29,294 27,346
Total current liabilities.................................................................................................................................... 110,781 103,769
Long-term debt, less current maturities.......................................................................................................... 73,495 72,359
Deferred income taxes .................................................................................................................................... 3,804 3,620
Other liabilities ............................................................................................................................................... 15,709 15,939
Total liabilities................................................................................................................................................ 203,789 195,687
Commitments and contingencies (Note 7)
Redeemable noncontrolling interests.............................................................................................................. 4,315 4,323
Equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding................... — —
Common stock, $0.01 par value - 3,000 shares authorized; 905 and 915 issued and outstanding......... 9 9
Retained earnings ................................................................................................................................... 97,250 96,036
Accumulated other comprehensive loss ................................................................................................. (2,535) (3,387)
Nonredeemable noncontrolling interests ........................................................................................................ 5,745 5,610
Total equity..................................................................................................................................................... 100,469 98,268
Total liabilities, redeemable noncontrolling interests and equity ............................................................ $ 308,573 $ 298,278
See Notes to the Condensed Consolidated Financial Statements
1

-- 3 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months Ended
June 30, Six Months Ended
June 30,
(in millions, except per share data) 2025 2024 2025 2024
Revenues:
Premiums......................................................................................................... $ 87,905 $ 76,897 $ 174,439 $ 154,885
Products ........................................................................................................... 13,564 12,211 26,600 24,120
Services............................................................................................................ 9,039 8,750 18,011 17,638
Investment and other income........................................................................... 1,108 997 2,141 2,008
Total revenues.......................................................................................................... 111,616 98,855 221,191 198,651
Operating costs:
Medical costs ................................................................................................... 78,585 65,458 151,996 131,193
Operating costs ................................................................................................ 13,778 13,162 27,372 27,239
Cost of products sold ....................................................................................... 13,019 11,340 25,409 22,396
Depreciation and amortization......................................................................... 1,084 1,020 2,145 2,017
Total operating costs................................................................................................ 106,466 90,980 206,922 182,845
Earnings from operations ..................................................................................... 5,150 7,875 14,269 15,806
Interest expense ....................................................................................................... (1,027) (985) (2,025) (1,829)
Loss on sale of subsidiary and subsidiaries held for sale ........................................ (41) (1,225) (56) (8,311)
Earnings before income taxes............................................................................... 4,082 5,665 12,188 5,666
Provision for income taxes ...................................................................................... (510) (1,244) (2,142) (2,466)
Net earnings............................................................................................................ 3,572 4,421 10,046 3,200
Earnings attributable to noncontrolling interests..................................................... (166) (205) (348) (393)
Net earnings attributable to UnitedHealth Group common shareholders....... $ 3,406 $ 4,216 $ 9,698 $ 2,807
Earnings per share attributable to UnitedHealth Group common
shareholders:......................................................................................................
Basic ................................................................................................................ $ 3.76 $ 4.58 $ 10.66 $ 3.05
Diluted ............................................................................................................. $ 3.74 $ 4.54 $ 10.61 $ 3.02
Basic weighted-average number of common shares outstanding ..................... 907 921 910 921
Dilutive effect of common share equivalents....................................................... 3 7 4 8
Diluted weighted-average number of common shares outstanding.................. 910 928 914 929
Anti-dilutive shares excluded from the calculation of dilutive effect of common
share equivalents.................................................................................................. 13 8 10 7
See Notes to the Condensed Consolidated Financial Statements
2

-- 4 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
Three Months Ended
June 30, Six Months Ended
June 30,
(in millions) 2025 2024 2025 2024
Net earnings....................................................................................................................... $ 3,572 $ 4,421 $ 10,046 $ 3,200
Other comprehensive income:
Gross unrealized gains (losses) on investment securities during the period............... 327 (75) 848 (365)
Income tax effect......................................................................................................... (75) 17 (194) 85
Total unrealized gains (losses), net of tax.............................................................. 252 (58) 654 (280)
Gross reclassification adjustment for net realized gains included in net earnings...... (17) (26) (27) (58)
Income tax effect......................................................................................................... 4 6 6 13
Total reclassification adjustment, net of tax ........................................................ (13) (20) (21) (45)
Foreign currency translation gains (losses) ................................................................ 131 8 219 (285)
Reclassification adjustment for translation losses included in net earnings............... — 86 — 4,214
Total foreign currency translation gains ................................................................ 131 94 219 3,929
Other comprehensive income ........................................................................................... 370 16 852 3,604
Comprehensive income....................................................................................................... 3,942 4,437 10,898 6,804
Comprehensive income attributable to noncontrolling interests ........................................ (166) (205) (348) (393)
Comprehensive income attributable to UnitedHealth Group common shareholders $ 3,776 $ 4,232 $ 10,550 $ 6,411
See Notes to the Condensed Consolidated Financial Statements
3

-- 5 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common Stock
Additional
Paid-In
Capital Retained
Earnings
Accumulated Other
Comprehensive Loss
Nonredeemable
Noncontrolling
Interests Total
Equity
Three months ended June 30,
(in millions) Shares Amount
Net
Unrealized
(Losses)
Gains on
Investments
Foreign
Currency
Translation
(Losses)
Gains
Balance at March 31, 2025 ................ 910 $ 9 $ — $ 97,934 $ (1,832) $ (1,073) $ 5,773 $ 100,811
Net earnings ....................................... 3,406 149 3,555
Other comprehensive income ............ 239 131 370
Issuances of common stock, and
related tax effects ........................... 1 — 196 196
Share-based compensation................. 229 229
Common share repurchases ............... (6) — (415) (2,090) (2,505)
Cash dividends paid on common
shares ($2.21 per share) ................. (2,000) (2,000)
Redeemable noncontrolling interests
fair value and other adjustments .... (10) (10)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests .......................................... (19) (19)
Distribution to nonredeemable
noncontrolling interests.................. (158) (158)
Balance at June 30, 2025 ................... 905 $ 9 $ — $ 97,250 $ (1,593) $ (942) $ 5,745 $ 100,469
Balance at March 31, 2024 ................ 920 $ 9 $ — $ 90,118 $ (2,218) $ (1,221) $ 5,682 $ 92,370
Net earnings ....................................... 4,216 158 4,374
Other comprehensive (loss) income... (78) 94 16
Issuances of common stock, and
related tax effects ........................... 1 — 196 196
Share-based compensation................. 210 210
Common share repurchases ............... — — 3 1 4
Cash dividends paid on common
shares ($2.10 per share) ................. (1,935) (1,935)
Redeemable noncontrolling interests
fair value and other adjustments .... (36) (36)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests .......................................... (338) (338)
Distribution to nonredeemable
noncontrolling interests.................. (185) (185)
Balance at June 30, 2024 ................... 921 $ 9 $ 373 $ 92,400 $ (2,296) $ (1,127) $ 5,317 $ 94,676
See Notes to the Condensed Consolidated Financial Statements
4

-- 6 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common Stock
Additional
Paid-In
Capital Retained
Earnings
Accumulated Other
Comprehensive Loss
Nonredeemable
Noncontrolling
Interests Total
Equity
Six months ended June 30,
(in millions) Shares Amount
Net
Unrealized
(Losses)
Gains on
Investments
Foreign
Currency
Translation
(Losses)
Gains
Balance at January 1, 2025 ................ 915 $ 9 $ — $ 96,036 $ (2,226) $ (1,161) $ 5,610 $ 98,268
Net earnings ....................................... 9,698 297 9,995
Other comprehensive income ............ 633 219 852
Issuances of common stock, and
related tax effects ........................... 2 — 379 379
Share-based compensation................. 591 591
Common share repurchases ............... (12) — (955) (4,572) (5,527)
Cash dividends paid on common
shares ($4.31 per share) ................. (3,912) (3,912)
Redeemable noncontrolling interests
fair value and other adjustments .... (15) (15)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests .......................................... 175 175
Distribution to nonredeemable
noncontrolling interests.................. (337) (337)
Balance at June 30, 2025 ................... 905 $ 9 $ — $ 97,250 $ (1,593) $ (942) $ 5,745 $ 100,469
Balance at January 1, 2024 ................ 924 $ 9 $ — $ 95,774 $ (1,971) $ (5,056) $ 5,665 $ 94,421
Net earnings ....................................... 2,807 307 3,114
Other comprehensive (loss) income... (325) 3,929 3,604
Issuances of common stock, and
related tax effects ........................... 3 — 438 438
Share-based compensation................. 562 562
Common share repurchases ............... (6) — (571) (2,517) (3,088)
Cash dividends paid on common
shares ($3.98 per share) ................. (3,664) (3,664)
Redeemable noncontrolling interests
fair value and other adjustments .... (56) (56)
Acquisition and other adjustments of
nonredeemable noncontrolling
interests .......................................... (319) (319)
Distribution to nonredeemable
noncontrolling interests.................. (336) (336)
Balance at June 30, 2024 ................... 921 $ 9 $ 373 $ 92,400 $ (2,296) $ (1,127) $ 5,317 $ 94,676
See Notes to the Condensed Consolidated Financial Statements
5

-- 7 of 30 --

UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Six Months Ended
June 30,
(in millions) 2025 2024
Operating activities
Net earnings.............................................................................................................................................................. $ 10,046 $ 3,200
Noncash items:
Depreciation and amortization ......................................................................................................................... 2,145 2,017
Deferred income taxes...................................................................................................................................... (87) (358)
Share-based compensation ............................................................................................................................... 572 594
Loss on sale of subsidiary and subsidiaries held for sale................................................................................. 56 8,311
Other, net.......................................................................................................................................................... 127 459
Net change in other operating items, net of effects from acquisitions and dispositions:
Accounts receivable ......................................................................................................................................... (1,681) (2,471)
Other assets ...................................................................................................................................................... (2,143) (4,121)
Medical costs payable ...................................................................................................................................... 4,371 777
Accounts payable and other liabilities ............................................................................................................. (480) 36
Unearned revenues ........................................................................................................................................... (282) (554)
Cash flows from operating activities........................................................................................................................ 12,644 7,890
Investing activities
Purchases of investments ......................................................................................................................................... (8,180) (10,130)
Sales of investments................................................................................................................................................. 5,181 5,288
Maturities of investments......................................................................................................................................... 4,326 4,621
Cash paid for acquisitions and other transactions, net of cash assumed .................................................................. (734) (3,031)
Purchases of property, equipment and capitalized software .................................................................................... (1,784) (1,596)
Loans to care providers - cyberattack ...................................................................................................................... — (8,100)
Repayments of care provider loans - cyberattack .................................................................................................... 1,293 604
Other, net.................................................................................................................................................................. (1,618) (1,413)
Cash flows used for investing activities................................................................................................................... (1,516) (13,757)
Financing activities
Common share repurchases...................................................................................................................................... (5,545) (3,072)
Cash dividends paid ................................................................................................................................................. (3,912) (3,664)
Proceeds from common stock issuances .................................................................................................................. 581 744
Repayments of long-term debt ................................................................................................................................. — (1,750)
(Repayments of) proceeds from short-term borrowings, net ................................................................................... (1,403) 8,615
Proceeds from issuance of long-term debt ............................................................................................................... 2,969 5,925
Customer funds administered................................................................................................................................... (25) 990
Other, net.................................................................................................................................................................. (513) (753)
Cash flows (used for) from financing activities ....................................................................................................... (7,848) 7,035
Effect of exchange rate changes on cash and cash equivalents................................................................................ 29 (44)
Increase in cash and cash equivalents, including cash within businesses held for sale ................................... 3,309 1,124
Less: net increase in cash within businesses held for sale ....................................................................................... (25) (265)
Net increase in cash and cash equivalents................................................................................................................ 3,284 859
Cash and cash equivalents, beginning of period.................................................................................................. 25,312 25,427
Cash and cash equivalents, end of period ............................................................................................................ $ 28,596 $ 26,286
See Notes to the Condensed Consolidated Financial Statements
6

-- 8 of 30 --

UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1. Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”)
is a health care and well-being company with a mission to help people live healthier lives and help make the health system work
better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are
working to help build a modern, high-performing health system through improved access, affordability, outcomes and
experiences for the individuals and organizations the Company is privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted
Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end
condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures
required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the
Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual
audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read
together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and
Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 as filed with the
SEC (2024 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments
necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and
judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and
goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve
matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is
included in earnings in the period in which the estimate is adjusted.
Revenues - Products and Services
As of June 30, 2025 and December 31, 2024, accounts receivable related to products and services were $9.8 billion and
$9.9 billion, respectively. As of June 30, 2025, revenue expected to be recognized in any future year related to remaining
performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less,
contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance
obligations, was $11.9 billion, of which approximately half is expected to be recognized in the next three years.
7

-- 9 of 30 --

2. Investments
A summary of debt securities by major security type is as follows:
(in millions) Amortized
Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses Fair
Value
June 30, 2025
Debt securities - available-for-sale:
U.S. government and agency obligations ............................. $ 4,189 $ 3 $ (186) $ 4,006
State and municipal obligations............................................ 7,234 7 (375) 6,866
Corporate obligations ........................................................... 24,044 106 (735) 23,415
U.S. agency mortgage-backed securities.............................. 10,341 8 (783) 9,566
Non-U.S. agency mortgage-backed securities...................... 2,875 7 (127) 2,755
Total debt securities - available-for-sale ...................................... 48,683 131 (2,206) 46,608
Debt securities - held-to-maturity:
U.S. government and agency obligations ............................. 448 1 (1) 448
State and municipal obligations............................................ 26 — (3) 23
Corporate obligations ........................................................... 19 — — 19
Total debt securities - held-to-maturity ......................................... 493 1 (4) 490
Total debt securities...................................................................... $ 49,176 $ 132 $ (2,210) $ 47,098
December 31, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations ............................. $ 4,600 $ 1 $ (274) $ 4,327
State and municipal obligations............................................ 7,357 2 (375) 6,984
Corporate obligations ........................................................... 24,391 56 (1,140) 23,307
U.S. agency mortgage-backed securities.............................. 10,577 1 (994) 9,584
Non-U.S. agency mortgage-backed securities...................... 2,890 2 (175) 2,717
Total debt securities - available-for-sale ...................................... 49,815 62 (2,958) 46,919
Debt securities - held-to-maturity:
U.S. government and agency obligations ............................. 444 — (2) 442
State and municipal obligations............................................ 28 — (2) 26
Corporate obligations ........................................................... 40 — — 40
Total debt securities - held-to-maturity ........................................ 512 — (4) 508
Total debt securities...................................................................... $ 50,327 $ 62 $ (2,962) $ 47,427
The Company held $5.4 billion and $4.9 billion of equity securities as of June 30, 2025 and December 31, 2024, respectively.
The Company’s investments in equity securities primarily consist of venture investments and employee savings plan related
investments. Additionally, the Company’s investments included $3.4 billion and $3.8 billion of equity method investments
primarily in operating businesses in the health care sector as of June 30, 2025 and December 31, 2024, respectively. The
allowance for credit losses on held-to-maturity securities at June 30, 2025 and December 31, 2024 was not material.
8

-- 10 of 30 --

The amortized cost and fair value of debt securities as of June 30, 2025, by contractual maturity, were as follows:
Available-for-Sale Held-to-Maturity
(in millions) Amortized
Cost Fair
Value Amortized
Cost Fair
Value
Due in one year or less ..................................................................................................... $ 3,530 $ 3,506 $ 319 $ 319
Due after one year through five years .............................................................................. 14,415 14,106 152 152
Due after five years through ten years.............................................................................. 11,983 11,485 5 5
Due after ten years............................................................................................................ 5,539 5,190 17 14
U.S. agency mortgage-backed securities.......................................................................... 10,341 9,566 — —
Non-U.S. agency mortgage-backed securities.................................................................. 2,875 2,755 — —
Total debt securities.......................................................................................................... $ 48,683 $ 46,608 $ 493 $ 490
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that
individual securities have been in a continuous unrealized loss position were as follows:
Less Than 12 Months 12 Months or Greater Total
(in millions) Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses Fair
Value
Gross
Unrealized
Losses
June 30, 2025
Debt securities - available-for-sale:
U.S. government and agency obligations.......... $ 1,377 $ (21) $ 1,833 $ (165) $ 3,210 $ (186)
State and municipal obligations......................... 2,116 (93) 4,037 (282) 6,153 (375)
Corporate obligations......................................... 4,988 (80) 10,214 (655) 15,202 (735)
U.S. agency mortgage-backed securities ........... 3,914 (110) 4,561 (673) 8,475 (783)
Non-U.S. agency mortgage-backed securities ... 300 (2) 1,636 (125) 1,936 (127)
Total debt securities - available-for-sale.................... $ 12,695 $ (306) $ 22,281 $ (1,900) $ 34,976 $ (2,206)
December 31, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations .......... $ 1,475 $ (51) $ 2,152 $ (223) $ 3,627 $ (274)
State and municipal obligations......................... 2,593 (58) 4,085 (317) 6,678 (375)
Corporate obligations......................................... 7,402 (213) 11,449 (927) 18,851 (1,140)
U.S. agency mortgage-backed securities ........... 4,791 (191) 4,674 (803) 9,465 (994)
Non-U.S. agency mortgage-backed securities ... 416 (5) 1,863 (170) 2,279 (175)
Total debt securities - available-for-sale.................... $ 16,677 $ (518) $ 24,223 $ (2,440) $ 40,900 $ (2,958)
The Company’s unrealized losses from debt securities as of June 30, 2025 were generated from approximately 28,000 positions
out of a total of 43,000 positions. The Company believes that it will timely collect the principal and interest due on its debt
securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate
increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s
assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt
securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company
evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit
deterioration since purchase. As of June 30, 2025, the Company did not have the intent to sell any of the available-for-sale debt
securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit
losses on available-for-sale debt securities at June 30, 2025 and December 31, 2024 was not material.
9

-- 11 of 30 --

3. Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values
disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of
three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy
classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in
Part II, Item 8, “Financial Statements and Supplementary Data” in the 2024 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair
value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair and
Carrying
Value
June 30, 2025
Cash and cash equivalents.............................................................................. $ 23,299 $ 5,297 $ — $ 28,596
Debt securities - available-for-sale:
U.S. government and agency obligations............................................... 3,876 130 — 4,006
State and municipal obligations ............................................................. — 6,866 — 6,866
Corporate obligations ............................................................................. — 22,942 473 23,415
U.S. agency mortgage-backed securities................................................ — 9,566 — 9,566
Non-U.S. agency mortgage-backed securities ....................................... — 2,755 — 2,755
Total debt securities - available-for-sale ........................................................ 3,876 42,259 473 46,608
Equity securities ............................................................................................. 1,879 213 207 2,299
Total assets at fair value ................................................................................. $ 29,054 $ 47,769 $ 680 $ 77,503
Percentage of total assets at fair value ........................................................... 37 % 62 % 1 % 100 %
December 31, 2024
Cash and cash equivalents.............................................................................. $ 25,248 $ 64 $ — $ 25,312
Debt securities - available-for-sale:
U.S. government and agency obligations............................................... 4,194 133 — 4,327
State and municipal obligations ............................................................. — 6,984 — 6,984
Corporate obligations ............................................................................. 29 22,841 437 23,307
U.S. agency mortgage-backed securities................................................ — 9,584 — 9,584
Non-U.S. agency mortgage-backed securities ....................................... — 2,717 — 2,717
Total debt securities - available-for-sale ........................................................ 4,223 42,259 437 46,919
Equity securities ............................................................................................. 1,859 24 65 1,948
Total assets at fair value ................................................................................. $ 31,330 $ 42,347 $ 502 $ 74,179
Percentage of total assets at fair value ........................................................... 42 % 57 % 1 % 100 %
There were no transfers in or out of Level 3 financial assets or liabilities during the six months ended June 30, 2025 or 2024.
10

-- 12 of 30 --

The following table presents a summary of fair value measurements by level and carrying values for certain financial
instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)
Quoted Prices
in Active
Markets
(Level 1)
Other
Observable
Inputs
(Level 2)
Unobservable
Inputs
(Level 3)
Total
Fair
Value
Total
Carrying
Value
June 30, 2025
Debt securities - held-to-maturity ........................................ $ 466 $ 24 $ — $ 490 $ 493
Long-term debt and other financing obligations.................. $ — $ 74,304 $ — $ 74,304 $ 79,193
December 31, 2024
Debt securities - held-to-maturity ........................................ $ 482 $ 26 $ — $ 508 $ 512
Long-term debt and other financing obligations.................. $ — $ 70,565 $ — $ 70,565 $ 75,604
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are
subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. The assets
and liabilities within our South American operations held for sale as of June 30, 2025 were measured at the lower of carrying
value or fair value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price
derived from Company-specific information and market conditions. There were no significant fair value adjustments for assets
and liabilities recorded during the six months ended June 30, 2025 or 2024.
4. Medical Costs Payable
The following table shows the components of the change in medical costs payable for the six months ended June 30:
(in millions) 2025 2024
Medical costs payable, beginning of period ........................................................................................................ $ 34,224 $ 32,395
Acquisitions (dispositions), net ........................................................................................................................... — (687)
Reported medical costs:
Current year ................................................................................................................................................. 152,316 131,583
Prior years.................................................................................................................................................... (320) (390)
Total reported medical costs................................................................................................................................ 151,996 131,193
Medical payments:
Payments for current year............................................................................................................................ (118,793) (102,288)
Payments for prior years.............................................................................................................................. (28,998) (27,887)
Total medical payments....................................................................................................................................... (147,791) (130,175)
Less: increase in medical costs payable included within businesses held for sale.............................................. (2) (179)
Medical costs payable, end of period .................................................................................................................. $ 38,427 $ 32,547
For the six months ended June 30, 2025 and 2024, prior years’ medical cost reserve development included no individual factors
that were significant. Medical costs payable included reserves for claims incurred by consumers but not yet reported to the
Company of $26.8 billion and $23.7 billion at June 30, 2025 and December 31, 2024, respectively.
11

-- 13 of 30 --

5. Short-Term Borrowings and Long-Term Debt
In June 2025, the Company issued $3.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages) Par Value
4.4%, June 2028............................................................................................................................................................ $ 500
4.65%, January 2031..................................................................................................................................................... 750
5.3%, June 2035............................................................................................................................................................ 1,000
5.95%, June 2055.......................................................................................................................................................... 750
For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2024 10-
K.
6. Dividends
In June 2025, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual
rate of $8.84 compared to $8.40 per share, which the Company had paid since June 2024. Declaration and payment of future
quarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions
change.
The following table provides details of the Company’s dividend payments during the six months ended June 30, 2025:
Payment Date Amount per Share Total Amount Paid
(in millions)
March 18 .................................................................................................................... $ 2.10 $ 1,912
June 24........................................................................................................................ 2.21 2,000
7. Commitments and Contingencies
Pending Acquisitions
As of June 30, 2025, the Company had entered into agreements to acquire companies in the health care sector, subject to
regulatory approval and other customary closing conditions. The total anticipated capital required for these acquisitions,
excluding the payoff of acquired indebtedness, was approximately $4 billion.
Legal Matters
The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits
brought by members, care providers, consumer advocacy organizations, customers, shareholders, and regulators, relating to the
Company’s businesses, including management and administration of health benefit plans and other services. These matters
include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to
health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of
costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where
the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present
novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the
early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to
estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be
incurred.
12

-- 14 of 30 --

Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These
include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services
(CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General (OIG),
the Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade
Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the
U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the
Consumer Financial Protection Bureau, the Defense Contract Audit Agency, the Food and Drug Administration and other
governmental authorities. Similarly, the Company’s international businesses are also subject to investigations, audits and
reviews by applicable foreign governments. The Company has also been responding to subpoenas, information requests and
investigations from governmental entities. The Company can provide no assurance as to the scope and outcome of these matters
and no assurance as to whether its business, financial condition or results of operations will be materially adversely affected.
Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters,
compliance with coding and other requirements under the Medicare risk-adjustment model. CMS and OIG have selected certain
of the Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and
supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to
payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the
Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15,
2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. In March 2025, a
Special Master appointed by the court issued a report recommending that the court enter summary judgment in the Company’s
favor on all remaining claims. In April 2025, the DOJ filed a motion asking the court to reject the Special Master’s report. The
Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.
8. Held for Sale
The Company’s planned sales of its remaining South American operations are expected to close within the year, subject to
regulatory and other customary closing conditions. Assets and liabilities held for sale have been included within prepaid
expenses and other current assets and other current liabilities on the Condensed Consolidated Balance Sheet, respectively.
The assets and liabilities of the held for sale disposal groups as of June 30, 2025, were as follows:
(in millions) Businesses
Held for Sale
Assets
Cash and cash equivalents.................................................................................................................................................. $ 244
Accounts receivable and other current assets..................................................................................................................... 674
Property, equipment and capitalized software ................................................................................................................... 719
Goodwill and other intangible assets ................................................................................................................................. 442
Other long-term assets........................................................................................................................................................ 292
Remeasurement of assets of businesses held for sale to fair value less cost to sell(1) ........................................................ (1,314)
Total assets.................................................................................................................................................................... $ 1,057
Liabilities
Medical costs payable ........................................................................................................................................................ $ 181
Accounts payable and other current liabilities ................................................................................................................... 368
Other long-term liabilities .................................................................................................................................................. 436
Total liabilities .............................................................................................................................................................. $ 985
(1) Includes the effect of $847 million of cumulative foreign currency translation losses and $50 million of noncontrolling interests.
13

-- 15 of 30 --

9. Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more
information on the Company’s segments, see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial
Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2024 10-K.
The following tables present reportable segment financial information:
Optum
(in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum
Eliminations Optum Corporate and
Eliminations Consolidated
Three Months Ended June 30, 2025
Revenues - unaffiliated customers:
Premiums................................... $ 83,019 $ 4,886 $ — $ — $ — $ 4,886 $ — $ 87,905
Products ..................................... — 65 44 13,455 — 13,564 — 13,564
Services...................................... 2,511 3,846 1,516 1,166 — 6,528 — 9,039
Total revenues - unaffiliated
customers....................................... 85,530 8,797 1,560 14,621 — 24,978 — 110,508
Total revenues - affiliated customers. — 15,953 3,236 23,790 (1,267) 41,712 (41,712) —
Investment and other income............. 573 455 32 48 — 535 — 1,108
Total revenues.................................... $ 86,103 $ 25,205 $ 4,828 $ 38,459 $ (1,267) $ 67,225 $ (41,712) $ 111,616
Total operating costs (a) .................... $ 84,028 $ 24,569 $ 3,830 $ 37,018 $ (1,267) $ 64,150 $ (41,712) $ 106,466
Earnings from operations................... $ 2,075 $ 636 $ 998 $ 1,441 $ — $ 3,075 $ — $ 5,150
Interest expense ................................. — — — — — — (1,027) (1,027)
Loss on sale of subsidiary and
subsidiaries held for sale................ (41) — — — — — — (41)
Earnings before income taxes............ $ 2,034 $ 636 $ 998 $ 1,441 $ — $ 3,075 $ (1,027) $ 4,082
Total assets ........................................ $ 129,587 $ 96,452 $ 33,716 $ 61,674 $ — $ 191,842 $ (12,856) $ 308,573
Purchases of property, equipment
and capitalized software ................ 193 306 289 98 — 693 — 886
Depreciation and Amortization ......... 221 296 351 216 — 863 — 1,084
Three Months Ended June 30, 2024
Revenues - unaffiliated customers:
Premiums................................... $ 70,950 $ 5,947 $ — $ — $ — $ 5,947 $ — $ 76,897
Products ..................................... — 62 41 12,108 — 12,211 — 12,211
Services...................................... 2,388 4,083 1,405 874 — 6,362 — 8,750
Total revenues - unaffiliated
customers....................................... 73,338 10,092 1,446 12,982 — 24,520 — 97,858
Total revenues - affiliated customers. — 16,576 3,070 19,373 (1,129) 37,890 (37,890) —
Investment and other income............. 528 382 27 60 — 469 — 997
Total revenues.................................... $ 73,866 $ 27,050 $ 4,543 $ 32,415 $ (1,129) $ 62,879 $ (37,890) $ 98,855
Total operating costs (a) .................... $ 69,862 $ 25,131 $ 3,997 $ 31,009 $ (1,129) $ 59,008 $ (37,890) $ 90,980
Earnings from operations................... $ 4,004 $ 1,919 $ 546 $ 1,406 $ — $ 3,871 $ — $ 7,875
Interest expense ................................. — — — — — — (985) (985)
Loss on sale of subsidiary and
subsidiaries held for sale................ (1,225) — — — — — — (1,225)
Earnings before income taxes............ $ 2,779 $ 1,919 $ 546 $ 1,406 $ — $ 3,871 $ (985) $ 5,665
Total assets ........................................ $ 109,441 $ 93,858 $ 34,244 $ 56,058 $ — $ 184,160 $ (7,545) $ 286,056
Purchases of property, equipment
and capitalized software ................ 187 230 344 92 — 666 — 853
Depreciation and Amortization ......... 221 277 316 206 — 799 — 1,020
(a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable
for each reportable segment.
14

-- 16 of 30 --

Optum
(in millions) UnitedHealthcare Optum Health Optum Insight Optum Rx Optum
Eliminations Optum Corporate and
Eliminations Consolidated
Six Months Ended June 30, 2025
Revenues - unaffiliated customers:
Premiums................................... $ 164,532 $ 9,907 $ — $ — $ — $ 9,907 $ — $ 174,439
Products ..................................... — 130 88 26,382 — 26,600 — 26,600
Services...................................... 5,087 7,720 3,017 2,187 — 12,924 — 18,011
Total revenues - unaffiliated
customers....................................... 169,619 17,757 3,105 28,569 — 49,431 — 219,050
Total revenues - affiliated customers. — 31,867 6,298 44,927 (2,453) 80,639 (80,639) —
Investment and other income............. 1,101 890 55 95 — 1,040 — 2,141
Total revenues.................................... $ 170,720 $ 50,514 $ 9,458 $ 73,591 $ (2,453) $ 131,110 $ (80,639) $ 221,191
Total operating costs (a) .................... $ 163,419 $ 48,264 $ 7,499 $ 70,832 $ (2,453) $ 124,142 $ (80,639) $ 206,922
Earnings from operations................... $ 7,301 $ 2,250 $ 1,959 $ 2,759 $ — $ 6,968 $ — $ 14,269
Interest expense ................................. — — — — — — (2,025) (2,025)
Loss on sale of subsidiary and
subsidiaries held for sale................ (56) — — — — — — (56)
Earnings before income taxes............ $ 7,245 $ 2,250 $ 1,959 $ 2,759 $ — $ 6,968 $ (2,025) $ 12,188
Total assets ........................................ $ 129,587 $ 96,452 $ 33,716 $ 61,674 $ — $ 191,842 $ (12,856) $ 308,573
Purchases of property, equipment
and capitalized software ................ 389 585 627 183 — 1,395 — 1,784
Depreciation and Amortization ......... 440 583 695 427 — 1,705 — 2,145
Six Months Ended June 30, 2024
Revenues - unaffiliated customers:
Premiums................................... $ 143,243 $ 11,642 $ — $ — $ — $ 11,642 $ — $ 154,885
Products ..................................... — 121 82 23,917 — 24,120 — 24,120
Services...................................... 4,917 8,053 3,107 1,561 — 12,721 — 17,638
Total revenues - unaffiliated
customers....................................... 148,160 19,816 3,189 25,478 — 48,483 — 196,643
Total revenues - affiliated customers. — 33,193 5,801 37,654 (2,145) 74,503 (74,503) —
Investment and other income............. 1,063 772 55 118 — 945 — 2,008
Total revenues.................................... $ 149,223 $ 53,781 $ 9,045 $ 63,250 $ (2,145) $ 123,931 $ (74,503) $ 198,651
Total operating costs (a) .................... $ 140,824 $ 49,963 $ 8,009 $ 60,697 $ (2,145) $ 116,524 $ (74,503) $ 182,845
Earnings from operations................... $ 8,399 $ 3,818 $ 1,036 $ 2,553 $ — $ 7,407 $ — $ 15,806
Interest expense ................................. — — — — — — (1,829) (1,829)
Loss on sale of subsidiary and
subsidiaries held for sale................ (8,311) — — — — — — (8,311)
Earnings before income taxes............ $ 88 $ 3,818 $ 1,036 $ 2,553 $ — $ 7,407 $ (1,829) $ 5,666
Total assets ........................................ $ 109,441 $ 93,858 $ 34,244 $ 56,058 $ — $ 184,160 $ (7,545) $ 286,056
Purchases of property, equipment
and capitalized software ................ 370 468 589 169 — 1,226 — 1,596
Depreciation and Amortization ......... 456 549 626 386 — 1,561 — 2,017
(a) Total operating costs include medical costs, operating costs, cost of products sold and depreciation and amortization, as applicable
for each reportable segment.
15

-- 17 of 30 --

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and
Notes and with our 2024 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8,
“Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms
“UnitedHealth Group,” the “Company,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of
Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and
Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic
conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and
uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking
statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2024 10-K
and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make
the health system work better for everyone. Our two distinct, yet complementary businesses — Optum and UnitedHealthcare —
are working to help build a modern, high-performing health system through improved access, affordability, outcomes and
experiences for the individuals and organizations we are privileged to serve.
We have four reportable segments:
• Optum Health;
• Optum Insight;
• Optum Rx; and
• UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement
and UnitedHealthcare Community & State.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” in our 2024 10-K and additional information on our segments
can be found in this Item 2 and in Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item
1 of this report.
Business Trends
Our businesses participate primarily in the United States health markets. We expect overall spending on health care to continue
to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements,
demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected
by a variety of factors, including macroeconomic conditions and regulatory changes, which could impact our results of
operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs,
including medical care patterns, the mix and health status of people served, inflation and labor market dynamics. For 2025, our
pricing trends and patient and member health status assumptions were well-short of the medical cost trends incurred,
significantly impacting our earnings. We continually evaluate and adjust our approach in each of the local markets we serve,
considering relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and
regulatory considerations, including minimum medical loss ratio thresholds and similar revenue adjustments. We seek to
balance growth and profitability across all these dimensions.
The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect
broad-based competition to continue as the industry adapts to individual and employer needs. Continued increased medical
costs may impact both future pricing and benefit design, including for our individual exchange products in markets we choose
to remain, and result in shifts between product categories for our employer benefits. These potential changes, along with certain
regulatory impacts, may result in decreased membership in future periods.
Medicare Advantage funding continues to be pressured, as discussed below in “Regulatory Trends and Uncertainties” and we
have observed increased care patterns as discussed below in “Medical Cost Trends,” which may impact pricing and benefit
design in future periods.
16

-- 18 of 30 --

Optum Health’s fully accountable value-based care businesses have been impacted by Medicare funding reductions and have
also seen continued medical cost trend pressures, which may impact future pricing in the markets we continue to participate.
The Medicaid redetermination process has caused a timing mismatch between the health status of people served through
Medicaid and state rate updates. Due to elevated care activity, specifically related to behavioral, pharmacy and home health,
there continues to be a mismatch between the updated rates in 2025 and underlying member acuity. The funding and payment
rate environment remains insufficient to meet the health needs of patients and creates the risk of continued downward pressure
on Medicaid margin percentages. We continue to take a prudent, market-sustainable posture for both new business and
maintenance of existing relationships. We continue to advocate for actuarially sound rates commensurate with our medical cost
trends and we remain dedicated to partnering with those states that are committed to the long-term viability of their programs.
Additionally, we expect some Medicaid membership losses in 2026 as a result of early adoption of recent legislation.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs.
We have observed increased care patterns, more notably related to physician and outpatient care, and to a lesser extent inpatient
and emergency room utilization, that are above what we expected and contemplated in our pricing and benefits design. We have
also observed an increase in health care unit costs and the intensity of services delivered, driven by increases in provider pricing
and additional services bundled per visit. Additionally, the member profile of newly added patients under value-based care
arrangements, people served in Medicare Advantage in markets where other plans exited, and peopled served within our
individual exchange business has contributed to increased medical costs. These trends may continue in future periods.
The Inflation Reduction Act (IRA) altered the Medicare Part D model and benefits, shifting more risk to plans, which results in
both increased premiums and medical costs. The IRA also changed the quarterly relationship of medical costs to premiums,
altering the seasonal progression and creating a more consistent relationship between medical costs and premiums throughout
the year.
We endeavor to mitigate medical cost increases by engaging hospitals, physicians and consumers with information and helping
them make clinically sound choices, with the objective of helping them achieve high-quality, affordable care. Additionally, we
have elevated our audit, clinical policy and payment integrity tools to protect customers and patients from unnecessary costs.
Regulatory Trends and Uncertainties
Medicare Advantage Rates. Medicare Advantage rate notices for numerous years have resulted in industry base rates well
below the industry forward medical cost trend, with the Final Notice for 2026 beginning to approach the industry forward
medical cost trend. Additionally, increased medical costs in 2025, which are significantly above initial cost trend estimates,
adds to the compounding impact of the previous multi-year rate shortfalls creating sustained pressure on the Medicare
Advantage program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to reflect a
patient’s health status and care resource needs, have and will result in reduced funding and potentially benefits for people,
especially those with some of the greatest health and social challenges.
As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures
and reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make
changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the
member premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on
a county-by-county basis where we will offer Medicare Advantage plans.
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select second quarter 2025 year-over-year operating comparisons to second quarter 2024 and other
financial results.
• Consolidated revenues grew 13%, UnitedHealthcare revenues grew 17% and Optum revenues grew 7%.
• UnitedHealthcare served 1.0 million more people, driven by growth in Medicare Advantage and commercial offerings.
• Consolidated earnings from operations of $5.2 billion compared to $7.9 billion last year, with 2025 impacted by elevated
medical cost trend and 2024 impacted by the Change Healthcare cyberattack.
• Diluted earnings per common share was $3.74.
• Cash flows from operations for the six months ended June 30, 2025 were $12.6 billion.
17

-- 19 of 30 --

RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per
share data)
Three Months Ended
June 30, Increase/
(Decrease) Six Months Ended
June 30, Increase/
(Decrease)
2025 2024 2025 vs. 2024 2025 2024 2025 vs. 2024
Revenues:
Premiums........................................... $ 87,905 $ 76,897 $ 11,008 14 % $ 174,439 $ 154,885 $ 19,554 13 %
Products............................................. 13,564 12,211 1,353 11 26,600 24,120 2,480 10
Services ............................................. 9,039 8,750 289 3 18,011 17,638 373 2
Investment and other income ............ 1,108 997 111 11 2,141 2,008 133 7
Total revenues ........................................... 111,616 98,855 12,761 13 221,191 198,651 22,540 11
Operating costs:
Medical costs..................................... 78,585 65,458 13,127 20 151,996 131,193 20,803 16
Operating costs.................................. 13,778 13,162 616 5 27,372 27,239 133 —
Cost of products sold......................... 13,019 11,340 1,679 15 25,409 22,396 3,013 13
Depreciation and amortization .......... 1,084 1,020 64 6 2,145 2,017 128 6
Total operating costs ................................. 106,466 90,980 15,486 17 206,922 182,845 24,077 13
Earnings from operations .......................... 5,150 7,875 (2,725) (35) 14,269 15,806 (1,537) (10)
Interest expense ......................................... (1,027) (985) (42) 4 (2,025) (1,829) (196) 11
Loss on sale of subsidiary and
subsidiaries held for sale ....................... (41) (1,225) 1,184 (97) (56) (8,311) 8,255 (99)
Earnings before income taxes ................... 4,082 5,665 (1,583) (28) 12,188 5,666 6,522 115
Provision for income taxes........................ (510) (1,244) 734 (59) (2,142) (2,466) 324 (13)
Net earnings............................................... 3,572 4,421 (849) (19) 10,046 3,200 6,846 214
Earnings attributable to noncontrolling
interests.................................................. (166) (205) 39 (19) (348) (393) 45 (11)
Net earnings attributable to UnitedHealth
Group common shareholders ................ $ 3,406 $ 4,216 $ (810) (19) % $ 9,698 $ 2,807 $ 6,891 245 %
Diluted earnings per share attributable to
UnitedHealth Group common
shareholders .......................................... $ 3.74 $ 4.54 $ (0.80) $ 10.61 $ 3.02 $ 7.59
Medical care ratio (a) ................................ 89.4 % 85.1 % 4.3 % 87.1 % 84.7 % 2.4 %
Operating cost ratio ................................... 12.3 13.3 (1.0) 12.4 13.7 (1.3)
Operating margin....................................... 4.6 8.0 (3.4) 6.5 8.0 (1.5)
Tax rate...................................................... 12.5 22.0 (9.5) 17.6 43.5 (25.9)
Net earnings margin (b)............................. 3.1 4.3 (1.2) 4.4 1.4 3.0
Return on equity (c)................................... 14.4 % 19.2 % (4.8) 20.6 % 6.4 % 14.2
(a) Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.
(b) Net earnings margin attributable to UnitedHealth Group shareholders.
(c) Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’
equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity
balances at the end of each of the quarters in the year presented.
18

-- 20 of 30 --

2025 RESULTS OF OPERATIONS COMPARED TO 2024 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenues
The increases in revenues were primarily driven by growth in people served through Medicare Advantage and those with higher
acuity needs within Medicaid, growth at Optum Rx and pricing trends.
Medical Costs and MCR
Medical costs increased primarily due to the IRA-driven impacts on Medicare Part D plans, elevated medical cost trend and
growth in people served through Medicare Advantage and those with higher acuity needs. The MCR increased as a result of the
revenue effects of the Medicare funding reductions; elevated medical cost trend; the member profile of newly added patients
under value-based care arrangements; and the impacts of market morbidity changes on our individual exchange offerings,
including the acceleration of anticipated future losses related to the second half of 2025; partially offset by the incremental
medical costs for accommodations made to care providers as a results of the Change Healthcare cyberattack incurred in 2024.
For the three months ended June 30, 2025, the MCR also increased due to the seasonal impacts of the IRA on Medicare Part D.
Operating Cost Ratio
The operating cost ratio decreased primarily due to revenue impacts of government programs, including the IRA-driven impacts
on Medicare Part D plans, operating cost management and our direct response efforts to the Change Healthcare cyberattack
incurred in 2024, partially offset by investments to support future growth.
Tax Rate
The effective income tax rate decreased due to tax benefits having significantly more impact due to lower pre-tax income in
2025, taxable earnings mix and the impact of the updated full year effective tax rate expectation. For the six months ended June
30, 2025, the tax rate was also lower due to non-deductible losses on the sale of subsidiary and subsidiaries held for sale in
2024.
Reportable Segments
See Note 9 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more
information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people
served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted
scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also
allow management and investors to evaluate and understand business mix, including the level and scope of services provided to
people, and pricing trends when comparing the metrics to revenue by segment.
19

-- 21 of 30 --

The following table presents a summary of the reportable segment financial information:
Three Months Ended
June 30, Increase/
(Decrease) Six Months Ended
June 30, Increase/
(Decrease)
(in millions, except percentages) 2025 2024 2025 vs. 2024 2025 2024 2025 vs. 2024
Revenues
UnitedHealthcare .......................... $ 86,103 $ 73,866 $ 12,237 17 % $ 170,720 $ 149,223 $ 21,497 14 %
Optum Health........................ 25,205 27,050 (1,845) (7) 50,514 53,781 (3,267) (6)
Optum Insight ....................... 4,828 4,543 285 6 9,458 9,045 413 5
Optum Rx.............................. 38,459 32,415 6,044 19 73,591 63,250 10,341 16
Optum eliminations............... (1,267) (1,129) (138) 12 (2,453) (2,145) (308) 14
Optum ........................................... 67,225 62,879 4,346 7 131,110 123,931 7,179 6
Eliminations .................................. (41,712) (37,890) (3,822) 10 (80,639) (74,503) (6,136) 8
Consolidated revenues .................. $ 111,616 $ 98,855 $ 12,761 13 % $ 221,191 $ 198,651 $ 22,540 11 %
Earnings from operations
UnitedHealthcare .......................... $ 2,075 $ 4,004 $ (1,929) (48) % $ 7,301 $ 8,399 $ (1,098) (13) %
Optum Health........................ 636 1,919 (1,283) (67) 2,250 3,818 (1,568) (41)
Optum Insight ....................... 998 546 452 83 1,959 1,036 923 89
Optum Rx.............................. 1,441 1,406 35 2 2,759 2,553 206 8
Optum ........................................... 3,075 3,871 (796) (21) 6,968 7,407 (439) (6)
Consolidated earnings from
operations.................................. $ 5,150 $ 7,875 $ (2,725) (35) % $ 14,269 $ 15,806 $ (1,537) (10) %
Operating margin
UnitedHealthcare .......................... 2.4 % 5.4 % (3.0) % 4.3 % 5.6 % (1.3) %
Optum Health........................ 2.5 7.1 (4.6) 4.5 7.1 (2.6)
Optum Insight ....................... 20.7 12.0 8.7 20.7 11.5 9.2
Optum Rx.............................. 3.7 4.3 (0.6) 3.7 4.0 (0.3)
Optum ........................................... 4.6 6.2 (1.6) 5.3 6.0 (0.7)
Consolidated operating margin..... 4.6 % 8.0 % (3.4) % 6.5 % 8.0 % (1.5) %
UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
Three Months Ended
June 30, Increase/
(Decrease) Six Months Ended
June 30, Increase/
(Decrease)
(in millions, except percentages) 2025 2024 2025 vs. 2024 2025 2024 2025 vs. 2024
UnitedHealthcare Employer & Individual - Domestic ... $ 18,950 $ 18,646 $ 304 2 % $ 38,016 $ 36,485 $ 1,531 4 %
UnitedHealthcare Employer & Individual - Global ....... 819 591 228 39 1,601 2,123 (522) (25)
UnitedHealthcare Employer & Individual - Total.. 19,769 19,237 532 3 39,617 38,608 1,009 3
UnitedHealthcare Medicare & Retirement ..................... 42,623 34,904 7,719 22 84,328 70,390 13,938 20
UnitedHealthcare Community & State........................... 23,711 19,725 3,986 20 46,775 40,225 6,550 16
Total UnitedHealthcare revenues ........................... $ 86,103 $ 73,866 $ 12,237 17 % $ 170,720 $ 149,223 $ 21,497 14 %
20

-- 22 of 30 --

The following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment
and funding arrangement:
June 30, Increase/(Decrease)
(in thousands, except percentages) 2025 2024 2025 vs. 2024
Commercial:
Risk-based................................................................................................................................. 8,440 8,735 (295) (3) %
Fee-based .................................................................................................................................. 21,530 20,835 695 3
Total Commercial ................................................................................................................... 29,970 29,570 400 1
Medicare Advantage .................................................................................................................... 8,350 7,770 580 7
Medicaid ...................................................................................................................................... 7,490 7,410 80 1
Medicare Supplement (Standardized).......................................................................................... 4,305 4,335 (30) (1)
Total Community and Senior.................................................................................................. 20,145 19,515 630 3
Total UnitedHealthcare - Medical .......................................................................................... 50,115 49,085 1,030 2
Supplemental Data:
Medicare Part D stand-alone................................................................................................... 2,800 3,065 (265) (9) %
South American businesses held for sale................................................................................ 1,165 1,330 (165) (12) %
UnitedHealthcare’s revenues increased due to the IRA-driven impacts on Medicare Part D plans and growth in the number of
people served through Medicare Advantage, fee-based commercial offerings and those with higher acuity needs, partially offset
by decreased people served through risk-based commercial offerings. Earnings from operations decreased primarily due to the
impacts of Medicare Advantage funding reductions, elevated medical cost trend, the impacts of market morbidity changes on
our individual exchange offerings, including the acceleration of anticipated future losses related to the second half of 2025 and
other write-offs and settlements, partially offset by the incremental medical costs for accommodations to support care providers
as a result of the Change Healthcare cyberattack incurred in 2024. For the six months ended June 30, 2025, decreased earnings
from operations was also partially offset by the seasonal impact of the IRA on Medicare Part D.
Optum
Total revenues increased primarily due to growth at Optum Rx, partially offset by Optum Health. Earnings from operations
decreased due to Optum Health, partially offset by the impacts of the Change Healthcare cyberattack incurred in 2024 and
Optum Rx. The results by segment were as follows:
Optum Health
Revenues at Optum Health decreased primarily due to the conversion of risk-based contracts, Medicare Advantage funding
reductions and the profile of members served, partially offset by growth in patients served under value-based arrangements.
Earnings from operations decreased due to Medicare Advantage funding reductions, the member profile of newly added
patients under value-based care arrangements, elevated medical cost trends and contractual settlements, partially offset by cost
management initiatives. For the six months ended June 30, 2025, decreased earnings from operations was also partially offset
by the incremental medical costs for accommodations to support care providers as a result of the Change Healthcare cyberattack
incurred in 2024. Optum Health served approximately 98 million people and 104 million people as of June 30, 2025 and
June 30, 2024, respectively.
Optum Insight
Revenues at Optum Insight increased due to decreased business disruption impacts related to the Change Healthcare
cyberattack. Earnings from operations at Optum Insight increased due to decreased business disruption impacts and direct
response costs related to the Change Healthcare cyberattack.
Optum Rx
Revenues and earnings from operations at Optum Rx increased due to higher script volumes from both new clients and growth
in existing clients and growth in pharmacy services. Earnings from operations also increased due to operating cost efficiencies.
Optum Rx fulfilled 414 million and 399 million adjusted scripts in the second quarters of 2025 and 2024, respectively.
21

-- 23 of 30 --

LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
Six Months Ended
June 30, Increase/
(Decrease)
(in millions) 2025 2024 2025 vs. 2024
Sources of cash:
Cash provided by operating activities.......................................................................................... $ 12,644 $ 7,890 $ 4,754
Issuances of short-term borrowings and long-term debt, net of repayments............................... 1,566 12,790 (11,224)
Proceeds from common stock issuances...................................................................................... 581 744 (163)
Customer funds administered ...................................................................................................... — 990 (990)
Repayments of care provider loans - cyberattack ........................................................................ 1,293 604 689
Sales and maturities of investments, net of purchases................................................................. 1,327 — 1,327
Total sources of cash............................................................................................................................ 17,411 23,018 (5,607)
Uses of cash:
Common stock repurchases ......................................................................................................... (5,545) (3,072) (2,473)
Cash paid for acquisitions and other transactions, net of cash assumed...................................... (734) (3,031) 2,297
Purchases of investments, net of sales of maturities .................................................................... — (221) 221
Purchases of property, equipment and capitalized software........................................................ (1,784) (1,596) (188)
Cash dividends paid ..................................................................................................................... (3,912) (3,664) (248)
Loans to care providers - cyberattack .......................................................................................... — (8,100) 8,100
Customer funds administered ...................................................................................................... (25) — (25)
Other ............................................................................................................................................ (2,131) (2,166) 35
Total uses of cash................................................................................................................................. (14,131) (21,850) 7,719
Effect of exchange rate changes on cash and cash equivalents ........................................................... 29 (44) 73
Increase in cash and cash equivalents, including cash within businesses held for sale....................... $ 3,309 $ 1,124 $ 2,185
Less: net increase in cash within businesses held for sale ................................................................... (25) (265) 240
Net increase in cash and cash equivalents ........................................................................................... $ 3,284 $ 859 $ 2,425
2025 Cash Flows Compared to 2024 Cash Flows
Increased cash flows provided by operating activities were driven by changes in working capital accounts, the seasonal impact
of the IRA on Medicare Part D and the impacts of the Change Healthcare cyberattack incurred in 2024. Other significant
changes in sources or uses of cash year-over-year included net repayments of loans to care providers in response to the Change
Healthcare cyberattack, decreased cash paid for acquisitions and increased net sales and maturities of investments, offset by
decreased net issuances of short-term borrowings and long-term debt, increased share repurchases and decreased customer
funds administered.
Financial Condition
As of June 30, 2025, our cash, cash equivalent, available-for-sale debt securities and marketable equity securities balances of
$77.3 billion included approximately $28.6 billion of cash and cash equivalents (of which $3.3 billion was available for general
corporate use), $46.6 billion of debt securities and $2.1 billion of investments in marketable equity securities. Given the
significant portion of our portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair
value of our financial assets to have a material impact on our liquidity or capital position. Our available-for-sale debt securities
portfolio had a weighted-average duration of 4.3 years and a weighted-average credit rating of “Double A” as of June 30, 2025.
When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the
weighted-average credit rating.
22

-- 24 of 30 --

Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital
resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2024 was disclosed in Part II, Item 7,
“Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2024 10-K. During the six
months ended June 30, 2025, there were no material changes to this previously disclosed information outside the ordinary
course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We
continually evaluate opportunities to expand our operations, including through internal development of new products, programs
and technology applications and business combinations.
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing
program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for
general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 8 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2024 10-
K.
As of June 30, 2025, we were in compliance with the various covenants under our bank credit facilities.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as to
meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information
on our long-term debt, see Note 5 of the Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of
this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and
Supplementary Data” in our 2024 10-K.
Credit Ratings. Our credit ratings as of June 30, 2025 were as follows:
Moody’s S&P Global Fitch A.M. Best
Ratings Outlook Ratings Outlook Ratings Outlook Ratings Outlook
Senior unsecured debt.......................... A2 Negative A+ Negative A Stable A Negative
Commercial paper................................ P-1 n/a A-1 n/a F1 n/a AMB-1+ n/a
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating
cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic
and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase
the cost of borrowing for us or limit our access to capital.
Regulatory Capital. As a result of an increased MCR impacting our regulated insurance and HMO subsidiaries, the specified
levels of required statutory capital required to be maintained are expected to increase. While we continue to maintain significant
levels of excess statutory capital in our subsidiaries, the amount of dividends our subsidiaries are able to pay to their parent
companies during the remainder of 2025 may be impacted. During the six months ended June 30, 2025, our domestic insurance
and HMO subsidiaries paid their parent companies dividends of $1.9 billion.
Share Repurchase Program. During the six months ended June 30, 2025, we repurchased approximately 12.1 million shares at
an average price of $454.82 per share. As of June 30, 2025, we had Board of Directors’ authorization to purchase up to 21.0
million shares of our common stock. The Board of Directors from time to time may further amend the share repurchase
program in order to increase the authorized number of shares which may be repurchased under the program.
Dividends. In June 2025, our Board of Directors increased our quarterly cash dividend to an annual rate of $8.84 compared to
$8.40 per share, which we had paid since June 2024. For more information on our dividend, see Note 6 of Notes to the
Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Pending Acquisitions. As of June 30, 2025, we have entered into agreements to acquire companies in the health care sector,
subject to regulatory approval and other customary closing conditions. The total anticipated consideration required for these
acquisitions, excluding the payoff of acquired indebtedness, was approximately $4 billion.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8,
“Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” included in Part II, Item 7 in our 2024 10-K.
23

-- 25 of 30 --

RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated
Financial Statements.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates,
which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and
estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent
liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends.
On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results,
however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical
accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included
in Part II, Item 7 in our 2024 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the
Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2024 10-
K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements
which are intended to take advantage of the “safe harbor” provisions of the federal securities laws. The words “believe,”
“expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify
forward-looking statements. These statements may contain information about financial prospects, economic conditions and
trends and involve risks and uncertainties. Actual results could differ materially from those that management expects,
depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs;
new or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data
security incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received
under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data
validation audits; the DOJ’s legal actions concerning our participation in the Medicare program; our ability to maintain and
achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if
our technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy
care services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to
our public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and
maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of
potential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government
investigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risk and uncertainties
associated with the sale of our remaining operations in South America; risks associated with public health crises arising from
large-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and
manage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill
and intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our
credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our
obligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend
payment cycle, or continue repurchasing shares of our common stock.
This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial
condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K.
By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks,
uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations
expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-
looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-
looking statements, except as required by law.
24

-- 26 of 30 --

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt
across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of
interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in
comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1%
point or 2% points as of June 30, 2025 on our investment income and interest expense per annum, and the fair value of our
investments and debt (in millions, except percentages):
June 30, 2025
Increase (Decrease) in Market Interest Rate
Investment
Income Per
Annum
Interest
Expense Per
Annum Fair Value of
Financial Assets Fair Value of
Financial Liabilities
2 %................................................................................... $ 734 $ 542 $ (4,202) $ (9,288)
1........................................................................................ 367 271 (2,150) (5,058)
(1) ..................................................................................... (367) (256) 2,202 6,107
(2) ..................................................................................... (734) (510) 4,416 13,549
Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on
the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.
ITEM 4. CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act
of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in
reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time
periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the
participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our
disclosure controls and procedures as of June 30, 2025. Based upon that evaluation, our Chief Executive Officer and Chief
Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of
June 30, 2025.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended June 30, 2025 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
25

-- 27 of 30 --

PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 7 of Notes to the Condensed
Consolidated Financial Statements included in Part I, Item 1 of this report.
ITEM 1A. RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item
1A, “Risk Factors” of our 2024 10-K, which could materially affect our business, financial condition or future results. The risks
described in our 2024 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that
we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2024 10-K.
ITEM 2. UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities (a)
Second Quarter 2025
For the Month Ended Total Number of
Shares Purchased Average Price Paid
Per Share
Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs
Maximum Number of
Shares That May Yet Be
Purchased Under The
Plans or Programs
(in millions) (in millions) (in millions)
April 30, 2025 ........................................ 3.8 $ 445.39 3.8 23.3
May 31, 2025 ......................................... 2.3 341.68 2.3 21.0
June 30, 2025 ......................................... — — — 21.0
Total ....................................................... 6.1 $ 407.06 6.1
(a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2024, the
Board of Directors amended our share repurchase program to authorize the repurchase of up to 35 million shares of our common stock in open market
purchases or other types of transactions (including prepaid or structured repurchase programs), in addition to all remaining shares authorized to be
repurchased under the Board’s 2018 renewal of the program. There is no established expiration date for the program. The Board of Directors from time
to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the
program.
ITEM 5. OTHER INFORMATION
Trading Arrangements
During the quarter ended June 30, 2025, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under the
Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities
intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1
trading arrangement.
26

-- 28 of 30 --

ITEM 6. EXHIBITS**
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company
files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the
Securities Exchange Act of 1934 under Commission File No. 1-10864.
3.1 Certificate of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the
Company’s Registration Statement on Form 8-A/A filed on July 1, 2015)
3.2 Amended and Restated Bylaws of UnitedHealth Group Incorporated, effective February 23, 2021 (incorporated
by reference to Exhibit 3.2 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on
February 26, 2021)
4.1 Amended and Restated Indenture, dated as of April 27, 2023, between UnitedHealth Group Incorporated and
Wilmington Trust Company, as successor trustee (incorporated by reference to Exhibit 4.1 to UnitedHealth
Group Incorporated’s Current Report on Form 8-K filed on April 28, 2023)
4.2 Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National
Association (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-3,
SEC File Number 333-149031, filed on February 4, 2008)
4.3 Supplemental Indenture, dated as of April 18, 2023, between UnitedHealth Group Incorporated and U.S. Bank
Trust Company, National Association, as trustee, relating to the 6.875% Senior Notes due 2038 (incorporated
by reference to Exhibit 4.1 to UnitedHealth Group Incorporated’s Current Report on Form 8-K filed on April
24, 2023)
*10.1 Employment Agreement, effective as of May 12, 2025, between United HealthCare Services, Inc. and Stephen
Hemsely
31.1 Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1 Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS XBRL Instance Document - the instance document does not appear in the Interactive Data File because its
XBRL tags are embedded within the Inline XBRL document.
101.SCH Inline XBRL Taxonomy Extension Schema Document.
101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
________________
* Denotes management contracts and compensation plans in which certain directors and named executive officers participate and which are being filed
pursuant to Item 601(b)(10)(iii)(A) of Regulation S-K.
** Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The
Company will furnish copies thereof to the SEC upon request.
27

-- 29 of 30 --

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
UNITEDHEALTH GROUP INCORPORATED
/s/ STEPHEN HEMSLEY Chair and Chief Executive Officer
(principal executive officer)
Dated: August 11, 2025
Stephen Hemsley
/s/ JOHN REX President and Chief Financial Officer
(principal financial officer) Dated: August 11, 2025
John Rex
/s/ THOMAS ROOS Senior Vice President and
Chief Accounting Officer
(principal accounting officer)
Dated: August 11, 2025
Thomas Roos
28

-- 30 of 30 --